Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Bioessays ; 37(5): 474-6, 2015 May.
Article in English | MEDLINE | ID: mdl-25731149

ABSTRACT

The recent explosion in the number of predatory journals has led to the appearance of questionable websites providing fake or spurious impact factors, which are analyzed and discussed here. We believe that academic associations, universities, and research funding bodies must take action to stop these questionable practices.


Subject(s)
Bibliometrics , Journal Impact Factor , Biomedical Research/standards
2.
Eur J Immunol ; 44(2): 469-79, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24165808

ABSTRACT

Programmed death-1 (PD-1) plays an important role in mediating immune tolerance through mechanisms that remain unclear. Herein, we investigated whether PD-1 prevents excessive host tissue damage during infection with the protozoan parasite, Toxoplasma gondii. Surprisingly, our results demonstrate that PD-1-deficient mice have increased susceptibility to T. gondii, with increased parasite cyst counts along with reduced type-1 cytokine responses (IL-12 and IFN-γ). PD-1⁻/⁻ DCs showed no cell intrinsic defect in IL-12 production in vitro. Instead, PD-1 neutralization via genetic or pharmacological approaches resulted in a striking increase in IL-10 release, which impaired type-1-inflammation during infection. Our results indicate that the absence of PD-1 increases IL-10 production even in the absence of infection. Although the possibility that such increased IL-10 protects against autoimmune damage is speculative, our results show that IL-10 suppresses the development of protective Th1 immune response after T. gondii infection.


Subject(s)
Interleukin-10/metabolism , Programmed Cell Death 1 Receptor/metabolism , Toxoplasmosis, Animal/metabolism , Animals , Inflammation/immunology , Inflammation/metabolism , Interferon-gamma/immunology , Interferon-gamma/metabolism , Interleukin-10/immunology , Interleukin-12/immunology , Interleukin-12/metabolism , Mice , Mice, Inbred C57BL , Programmed Cell Death 1 Receptor/immunology , Th1 Cells/immunology , Th1 Cells/metabolism , Toxoplasma/immunology , Toxoplasma/metabolism , Toxoplasmosis, Animal/immunology
3.
Mediators Inflamm ; 2013: 167086, 2013.
Article in English | MEDLINE | ID: mdl-24222935

ABSTRACT

Statins are pharmacological inhibitors of the activity of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR), an enzyme responsible for the synthesis of cholesterol. Some recent experimental studies have shown that besides their effects on the primary and secondary prevention of cardiovascular diseases, statins may also have beneficial anti-inflammatory effects through diverse mechanisms. On the other hand, the induction and activity of regulatory T cells (Treg) are key processes in the prevention of pathology during chronic inflammatory and autoimmune diseases. Hence, strategies oriented towards the therapeutic expansion of Tregs are gaining special attention among biomedical researchers. The potential effects of statins on the biology of Treg are of particular importance because of their eventual application as in vivo inducers of Treg in the treatment of multiple conditions. In this paper we review the experimental evidence pointing out to a potential effect of statins on the role of regulatory T cells in different conditions and discuss its potential clinical significance.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , T-Lymphocytes, Regulatory/drug effects , T-Lymphocytes, Regulatory/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Antigen-Presenting Cells/cytology , Autoimmune Diseases/metabolism , Cell Movement/drug effects , Cholesterol/blood , Dendritic Cells/cytology , Gene Expression Regulation , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Inflammation/metabolism , Mice , Phenotype , Th1 Cells/drug effects
4.
Adv Ther ; 40(6): 2836-2854, 2023 06.
Article in English | MEDLINE | ID: mdl-37129772

ABSTRACT

INTRODUCTION: The KEYNOTE-054 trial found that adjuvant treatment with pembrolizumab improved recurrence-free survival versus placebo in completely resected high-risk stage III melanoma patients. We assessed the cost-effectiveness of adjuvant pembrolizumab in Colombia compared with watchful waiting, a widely used strategy despite the high risk of recurrence with surgery alone. METHODS: A four-health state [recurrence-free (RF), locoregional recurrence (LR), distant metastases (DM), and death) Markov model was developed to assess the lifetime medical costs and outcomes (3% annual discount), along with cost-effectiveness ratios (ICERs). The transitions from the RF and LR states were modeled using KEYNOTE-054 data, and those from the DM state were modeled using data from the KEYNOTE-006 trial and a network meta-analysis of advanced treatments received after adjuvant pembrolizumab and watchful waiting. The health state utilities were derived from KEYNOTE-054 Euro-QoL data and literature. Costs are expressed in 2021 Colombian pesos (COP). RESULTS: Over a 46-year time horizon, patients on adjuvant pembrolizumab and watchful waiting were estimated to gain 9.69 and 7.56 quality-adjusted life-years (QALYs), 10.83 and 8.65 life-years (LYs), and incur costs of COP 663,595,726 and COP 563,237,206, respectively. The proportion of LYs spent in RF state was 84.63% for pembrolizumab and 72.13% for watchful waiting, yielding lower subsequent treatment, disease management, and terminal care costs for pembrolizumab. Adjuvant pembrolizumab improved survival by 2.18 LYs and 2.13 QALYs versus watchful waiting. The ICER per QALY was COP 47,081,917, primarily driven by recurrence rates and advanced melanoma treatments. The deterministic sensitivity analysis results were robust and consistent across various reasonable inputs and alternative scenarios. At a willingness-to-pay threshold of COP 69,150,201 per QALY, the probability of pembrolizumab being cost-effective was 65.70%. CONCLUSION: Pembrolizumab is cost-effective as an adjuvant treatment compared to watchful waiting among patients with high-risk stage III melanoma after complete resection in Colombia.


Subject(s)
Melanoma , Quality of Life , Humans , Cost-Benefit Analysis , Colombia , Neoplasm Recurrence, Local/drug therapy , Melanoma/drug therapy , Melanoma/surgery , Quality-Adjusted Life Years , Adjuvants, Immunologic/therapeutic use , Lymph Nodes/pathology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Melanoma, Cutaneous Malignant
5.
J Immunol ; 184(3): 1148-52, 2010 Feb 01.
Article in English | MEDLINE | ID: mdl-20042586

ABSTRACT

An effective innate immune recognition of the intracellular protozoan parasite Trypanosoma cruzi is critical for host resistance against Chagas disease, a severe and chronic illness that affects millions of people in Latin America. In this study, we evaluated the participation of nucleotide-binding oligomerization domain (Nod)-like receptor proteins in host response to T. cruzi infection and found that Nod1-dependent, but not Nod2-dependent, responses are required for host resistance against infection. Bone marrow-derived macrophages from Nod1(-/-) mice showed an impaired induction of NF-kappaB-dependent products in response to infection and failed to restrict T. cruzi infection in presence of IFN-gamma. Despite normal cytokine production in the sera, Nod1(-/-) mice were highly susceptible to T. cruzi infection, in a similar manner to MyD88(-/-) and NO synthase 2(-/-) mice. These studies indicate that Nod1-dependent responses account for host resistance against T. cruzi infection by mechanisms independent of cytokine production.


Subject(s)
Chagas Disease/immunology , Immunity, Innate , Nod1 Signaling Adaptor Protein/physiology , Trypanosoma cruzi/immunology , Animals , Chagas Disease/genetics , Chagas Disease/metabolism , Genetic Predisposition to Disease , Immunity, Innate/genetics , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Myeloid Differentiation Factor 88/physiology , Nod1 Signaling Adaptor Protein/deficiency , Nod1 Signaling Adaptor Protein/genetics , Nod2 Signaling Adaptor Protein/deficiency , Nod2 Signaling Adaptor Protein/genetics , Signal Transduction/genetics , Signal Transduction/immunology , Toll-Like Receptors/physiology
6.
Infect Immun ; 79(5): 1873-81, 2011 May.
Article in English | MEDLINE | ID: mdl-21357717

ABSTRACT

Trypanosoma cruzi infection causes intense myocarditis, leading to cardiomyopathy and severe cardiac dysfunction. Protective adaptive immunity depends on balanced signaling through a T cell receptor and coreceptors expressed on the T cell surface. Such coreceptors can trigger stimulatory or inhibitory signals after binding to their ligands in antigen-presenting cells (APC). T. cruzi modulates the expression of coreceptors in lymphocytes after infection. Deregulated inflammation may be due to unbalanced expression of these molecules. Programmed death cell receptor 1 (PD-1) is a negative T cell coreceptor that has been associated with T cell anergy or exhaustion and persistent intracellular infections. We aimed to study the role of PD-1 during T. cruzi-induced acute myocarditis in mice. Cytometry assays showed that PD-1 and its ligands are strongly upregulated in lymphocytes and APC in response to T. cruzi infection in vivo and in vitro. Lymphocytes infiltrating the myocardium exhibited high levels of expression of these molecules. An increased cardiac inflammatory response was found in mice treated with blocking antibodies against PD-1, PD-L1, and to a lesser extent, PD-L2, compared to that found in mice treated with rat IgG. Similar results in PD-1(-/-) mice were obtained. Moreover, the PD-1 blockade/deficiency led to reduced parasitemia and tissue parasitism but increased mortality. These results suggest the participation of a PD-1 signaling pathway in the control of acute myocarditis induced by T. cruzi and provide additional insight into the regulatory mechanisms in the pathogenesis of Chagas' disease.


Subject(s)
Antigens, Surface/immunology , Apoptosis Regulatory Proteins/immunology , Chagas Cardiomyopathy/immunology , Signal Transduction/immunology , T-Lymphocytes/immunology , Trypanosoma cruzi/immunology , Animals , Antigens, Surface/metabolism , Apoptosis Regulatory Proteins/metabolism , Cell Separation , Chagas Cardiomyopathy/metabolism , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Fluorescent Antibody Technique , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mice, Knockout , Programmed Cell Death 1 Receptor , Reverse Transcriptase Polymerase Chain Reaction
7.
Immunol Cell Biol ; 88(8): 825-33, 2010.
Article in English | MEDLINE | ID: mdl-20404835

ABSTRACT

Neospora caninum is an apicomplexan parasite responsible for major economic losses due to abortions in cattle. Toll-like receptors (TLRs) sense specific microbial products and direct downstream signaling pathways in immune cells, linking innate, and adaptive immunity. Here, we analyze the role of TLR2 on innate and adaptive immune responses during N. caninum infection. Inflammatory peritoneal macrophages and bone marrow-derived dendritic cells exposed to N. caninum-soluble antigens presented an upregulated expression of TLR2. Increased receptor expression was correlated to TLR2/MyD88-dependent antigen-presenting cell maturation and pro-inflammatory cytokine production after stimulation by antigens. Impaired innate responses observed after infection of mice genetically deficient for TLR2((-/-)) was followed by downregulation of adaptive T helper 1 (Th1) immunity, represented by diminished parasite-specific CD4(+) and CD8(+) T-cell proliferation, IFN-γ:interleukin (IL)-10 ratio, and IgG subclass synthesis. In parallel, TLR2(-/-) mice presented higher parasite burden than wild-type (WT) mice at acute and chronic stages of infection. These results show that initial recognition of N. caninum by TLR2 participates in the generation of effector immune responses against N. caninum and imply that the receptor may be a target for future prophylactic strategies against neosporosis.


Subject(s)
Coccidiosis/immunology , Dendritic Cells/metabolism , Macrophages, Peritoneal/metabolism , Neospora/immunology , Toll-Like Receptor 2/metabolism , Animals , Bone Marrow/pathology , Cattle , Cell Differentiation/genetics , Cell Growth Processes/genetics , Cells, Cultured , Coccidiosis/genetics , Coccidiosis/metabolism , Cytokines/genetics , Cytokines/metabolism , Dendritic Cells/immunology , Dendritic Cells/parasitology , Dendritic Cells/pathology , Gene Expression Regulation , Inflammation Mediators/metabolism , Macrophages, Peritoneal/immunology , Macrophages, Peritoneal/parasitology , Macrophages, Peritoneal/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Neospora/pathogenicity , Th1-Th2 Balance , Toll-Like Receptor 2/genetics
8.
Mem Inst Oswaldo Cruz ; 104 Suppl 1: 236-45, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19753479

ABSTRACT

Trypanosoma cruzi infection triggers substantial production of nitric oxide (NO), which has been shown to have protective and toxic effects on the host's immune system. Sensing of trypomastigotes by phagocytes activates the inducible NO-synthase (NOS2) pathway, which produces NO and is largely responsible for macrophage-mediated killing of T. cruzi. NO is also responsible for modulating virtually all steps of innate and adaptive immunity. However, NO can also cause oxidative stress, which is especially damaging to the host due to increased tissue damage. The cytokines IFN-gamma and TNF-alpha, as well as chemokines, are strong inducers of NOS2 and are produced in large amounts during T. cruzi acute infection. Conversely, TGF-beta and IL-10 negatively regulate NO production. Here we discuss the recent evidence describing the mechanisms by which NO is able to exert its antimicrobial and immune regulatory effects, the mechanisms involved in the oxidative stress response during infection and the implications of NO for the development of therapeutic strategies against T. cruzi.


Subject(s)
Chagas Disease/immunology , Immune System/metabolism , Nitric Oxide Synthase Type II/immunology , Nitric Oxide/immunology , Trypanosoma cruzi/immunology , Chagas Disease/metabolism , Humans , Immune System/parasitology , Nitric Oxide/biosynthesis , Nitric Oxide Synthase Type II/metabolism , Oxidative Stress
9.
Hematol Transfus Cell Ther ; 41(3): 262-267, 2019.
Article in English | MEDLINE | ID: mdl-31085149

ABSTRACT

INTRODUCTION: Infection by Trypanosoma cruzi is challenging to blood bank supplies in terms of accurate diagnosis, mostly due to its clinical complexity. Infected individuals may remain asymptomatic for years, albeit they may have circulating parasites potentially transferable to eventual receptors of a transfusion. OBJECTIVE: Although risk donors are systematically excluded through a survey, an important residual risk for transmission remains, evidencing the need to implement additional actions for the detection of T. cruzi in blood banks. METHOD: A review of the scientific literature is presented with the objective of identifying relevant publications on this subject. RESULTS: We discuss the diagnostic considerations of this chronic infection on transfusion medicine and some recent advances in the processing of blood and derivatives units. CONCLUSION: Finally, recommendations are made on how the transmission of T. cruzi can be avoided through the implementation of better diagnostic and pathogen control measures at blood banks.

10.
Microbes Infect ; 10(7): 825-33, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18538611

ABSTRACT

The infection with Trypanosoma cruzi leads to a vigorous and apparently uncontrolled inflammatory response in the heart. Although the parasites trigger specific immune response, the infection is not completely cleared out, a phenomenon that in other parasitic infections has been attributed to CD4+CD25+ T cells (Tregs). Then, we examined the role of natural Tregs and its signaling through CD25 and GITR in the resistance against infection with T. cruzi. Mice were treated with mAb against CD25 and GITR and the parasitemia, mortality and heart pathology analyzed. First, we demonstrated that CD4+CD25+GITR+Foxp3+ T cells migrate to the heart of infected mice. The treatment with anti-CD25 or anti-GITR resulted in increased mortality of these infected animals. Moreover, the treatment with anti-GITR enhanced the myocarditis, with increased migration of CD4+, CD8+, and CCR5+ leukocytes, TNF-alpha production, and tissue parasitism, although it did not change the systemic nitric oxide synthesis. These data showed a limited role for CD25 signaling in controlling the inflammatory response during this protozoan infection. Also, the data suggested that signaling through GITR is determinant to control of the heart inflammation, parasite replication, and host resistance against the infection.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Chagas Disease/immunology , T-Lymphocytes, Regulatory/immunology , Trypanosoma cruzi/immunology , Animals , CD4-Positive T-Lymphocytes/chemistry , CD8-Positive T-Lymphocytes/immunology , Female , Forkhead Transcription Factors/analysis , Glucocorticoid-Induced TNFR-Related Protein , Interleukin-2 Receptor alpha Subunit/analysis , Interleukin-2 Receptor alpha Subunit/antagonists & inhibitors , Interleukin-2 Receptor alpha Subunit/immunology , Mice , Myocardium/pathology , Parasitemia , Receptors, Nerve Growth Factor/antagonists & inhibitors , Receptors, Nerve Growth Factor/immunology , Receptors, Tumor Necrosis Factor/antagonists & inhibitors , Receptors, Tumor Necrosis Factor/immunology , Survival Analysis , T-Lymphocyte Subsets/immunology , T-Lymphocytes, Regulatory/chemistry , Tumor Necrosis Factor-alpha/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL